X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
TRM-201 (rofecoxib), COX-2 selective NSAID, as a potential treatment option for people living with pain whose needs are not satisfied by traditional NSAIDs. Rofecoxib was shown to have no effect on bleeding time and was the only COX-2 selective NSAID ever approved in the U.S.
Lead Product(s): Rofecoxib
Therapeutic Area: Neurology Product Name: TRM-201
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2022
Details:
Oral tablet formulation of TRM-201 (rofecoxib), has been shown to reach maximum plasma concentrations at two hours after dosing (versus three hours for historical VIOXX),7 which Tremeau believes could lead to faster onset of action, for people suffering from migraine.
Lead Product(s): Rofecoxib
Therapeutic Area: Neurology Product Name: TRM-201
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 14, 2022
Details:
Topical reformulation of oral medication Vioxx (rofecoxib), a COX-2 specific NSAID, aims to alleviate osteoarthritis-related pain of knee and joints in U.S. alone without opioids or adverse side effects due to systemic exposure associated with oral NSAID dosing.
Lead Product(s): Rofecoxib
Therapeutic Area: Musculoskeletal Product Name: Vioxx
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2022
Details:
Patent covers a reformulation of Vioxx (rofecoxib) called RelῩva, a COX-2 specific NSAID, from an oral to topical formulation with the intention of alleviating osteoarthritis-related pain of knee and joint pain, and reducing need for opioids in certain patient populations.
Lead Product(s): Rofecoxib
Therapeutic Area: Musculoskeletal Product Name: RelYva
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2022
Details:
The patent covers a reformulation of COX-2 specific NSAID, RelῩva (rofecoxib), to provide those suffering from osteoarthritis a long-lasting non-opioid option for pain relief and reducing the need for opioids in certain patient populations.
Lead Product(s): Rofecoxib
Therapeutic Area: Musculoskeletal Product Name: Relÿva
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2022
Details:
Tremeau is developing TRM-201 (rofecoxib), a COX-2 selective non-steroidal anti-inflammatory drug (NSAID), as a potential new treatment option for people with bleeding disorders who also suffer from painful conditions.
Lead Product(s): Rofecoxib
Therapeutic Area: Musculoskeletal Product Name: TRM-201
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
